Beijing Tiantan Biological Products Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Beijing Tiantan Biological Products Co., Ltd. carries a market capitalization of 23.55B, placing it among publicly traded companies globally. Its enterprise value stands at 33.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 23.55B |
| Enterprise Value | 33.53B |
Share Statistics
Beijing Tiantan Biological Products Co., Ltd. currently has 1.98B shares outstanding.
| Shares Outstanding | 1.98B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Beijing Tiantan Biological Products Co., Ltd. trades at a trailing price-to-earnings ratio of 40.31. The price-to-sales ratio is 6.84, and the price-to-book ratio stands at 3.50.
| PE Ratio | 40.31 |
| PS Ratio | 6.84 |
| PB Ratio | 3.50 |
| P/TBV Ratio | 2.35 |
| P/FCF Ratio | 60.58 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Beijing Tiantan Biological Products Co., Ltd. trades at an EV/EBITDA multiple of 24.68 and an EV/FCF ratio of 63.74. The EV/Sales ratio of 7.23 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 24.68 provides insight into valuation relative to core operating earnings.
| EV / Sales | 7.23 |
| EV / EBITDA | 24.68 |
| EV / EBIT | 24.68 |
| EV / FCF | 63.74 |
Financial Position
Beijing Tiantan Biological Products Co., Ltd. maintains a current ratio of 8.82, meaning it holds 8.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.59, indicating moderate leverage, while an interest coverage ratio of 384.32 demonstrates strong ability to service its debt obligations.
| Current Ratio | 8.82 |
| Quick Ratio | 2.00 |
| Debt / Equity | 0.59 |
| Debt / EBITDA | 0.07 |
| Interest Coverage | 384.32 |
Financial Efficiency
Beijing Tiantan Biological Products Co., Ltd. posts a return on equity of 8.89 and a return on invested capital of 7.12.
| Return on Equity (ROE) | 8.89 |
| Return on Assets (ROA) | 4.78 |
| Return on Invested Capital (ROIC) | 7.12 |
| Return on Capital Employed (ROCE) | 3.98 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.66 |
Taxes
Over the trailing twelve months, Beijing Tiantan Biological Products Co., Ltd. has paid 253.60M in income taxes, reflecting an effective tax rate of 19.06.
| Income Tax | 253.60M |
| Effective Tax Rate | 19.06 |
Stock Price Statistics
Beijing Tiantan Biological Products Co., Ltd.'s stock has declined approximately -39.81809% over the past 52 weeks. The 50-day moving average sits at 13.16, while the 200-day moving average is 15.98.
| Beta (5Y) | N/A |
| 52-Week Price Change | -39.81809% |
| 50-Day Moving Average | 13.16 |
| 200-Day Moving Average | 15.98 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Beijing Tiantan Biological Products Co., Ltd. generated 4.64B in revenue and converted that into 786.43M in net income, yielding earnings per share of 0.51. EBITDA reached 1.36B, while operating income came in at 1.36B.
| Revenue | 4.64B |
| Gross Profit | 1.95B |
| Operating Income | 1.36B |
| Pretax Income | 1.33B |
| Net Income | 786.43M |
| EBITDA | 1.36B |
| EBIT | 1.36B |
| Earnings Per Share (EPS) | 0.51 |
Balance Sheet
Beijing Tiantan Biological Products Co., Ltd. holds 1.89B in cash and equivalents against 91.80M in total debt, resulting in a net debt position of -1.89B. Total book value stands at 9.06B, with working capital of 7.41B providing operational flexibility.
| Cash & Cash Equivalents | 1.89B |
| Total Debt | 91.80M |
| Net Debt | -1.89B |
| Equity (Book Value) | 9.06B |
| Book Value Per Share | 4.32 |
| Working Capital | 7.41B |
Cash Flow
After subtracting -523.20M in capital expenditures, free cash flow totaled -523.20M - equivalent to -0.25 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -523.20M |
| Free Cash Flow | -523.20M |
| FCF Per Share | -0.25 |
Margins
Beijing Tiantan Biological Products Co., Ltd. operates with a gross margin of 42.07, reflecting its pricing power and cost economics. The operating margin of 29.30 and net profit margin of 16.96 provide insight into operational efficiency.
| Gross Margin | 42.07 |
| Operating Margin | 29.30 |
| Pretax Margin | 28.69 |
| Profit Margin | 16.96 |
| EBITDA Margin | 29.30 |
Dividends & Yields
The company's payout ratio of 0.02 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | 0.02 |
| Shareholder Yield | 0.60 |
| FCF Yield | 1.65 |
Stock Splits
Beijing Tiantan Biological Products Co., Ltd.'s most recent stock split took place on June 20, 2024 with a 5:6 split ratio.
| Last Split Date | 6/20/2024 |
| Split Ratio | 5:6 |
Scores
Beijing Tiantan Biological Products Co., Ltd. posts an Altman Z-Score of 18.04, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 18.04 |